anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A tetracycline antibiotic is solubilised in aqueous solution by the addition of a soluble non-toxic source of alkaline earth ions and a pyridine derivative having the formula:  <FORM:0845454/IV(b)/1> wherein R is hydrogen or a N-alkylcarbamyl, N-alkanolcarbamyl, hydrazinocarbonyl, hydroxyl, hydroxyalkyl, alkoxycarbonyl or carboxyl radical or a salt of a carboxyl group with a soluble non-toxic metal; R1 is hydrogen or a methyl group and R11 and R111 are each hydrogen or a hydroxymethyl group.  The tetracycline antibiotic is tetracycline, chlortetracycline, oxytetracycline, bromtetracycline or soluble salts thereof such as the hydrochloride and sulphate. Sources of alkaline earth ions are the chloride, sulphate, citrate, ascorbate, pantotherate, gluconate and lactate of calcium or magnesium.  The alkaline earth ion and the pyridine derivative may be combined, e.g. magnesium nicotinate.  One or more pyridine derivatives may be present.  Examples are nicotinamide, isonicotinamide, N-ethanol nicotinamide, N-methyl nicotinamide, picolinamide, nicotinic acid hydrazide, isonicotinic acid hydrazide, methyl nicotinate, methyl isonicotinate, sodium nicotinate, pyridoxine hydrochloride, 4-propanol pyridine and 2-propanol pyridine.  The molecular ratio of tetracycline antibiotic : alkaline earth ions : pyridine compound is at least 1:1:4 or 1: 1/2 :40 and is preferably 1:2.5:8.  Specification 793,558 is referred to.ALSO:A tetracycline antibiotic composition of enhanced solubility and stability which is, or is adapted on addition of water to provide, a clear aqueous solution and comprises a tetracycline antibiotic, a soluble non-toxic source of alkaline earth ions, and a pyridine derivative having the formula:  <FORM:0845454/VI/1> wherein R is hydrogen or a N-alkylcarbamyl, N-alkanolcarbamyl, hydrazinocarbonyl, hydroxyl, hydroxyalkyl, alkoxycarbonyl, or carboxyl radical or a salt of a carboxyl group with a soluble non-toxic metal; R1 is hydrogen or a methyl group and R11 and R111 are each hydrogen or a hydroxy-methyl group.  The tetracycline antibiotic is tetracycline, chlortetracycline, oxytetracycline, bromtetracycline or soluble salts thereof such as the hydrochloride and sulphate. sources of alkaline earth ions are the chloride, sulphate, citrate, ascorbate, pantothenate, gluconate and lactate of calcium or magnesium.  The alkaline earth ion and the pyridine derivative may be combined e.g. magnesium nicotinate.  One or more pyridene derivatives may be present.  Examples thereof are nicotinamide, isonicotinamide, N-ethanol nicotinamide, N-methyl nicotinamide, picolinamide, nicotinic acid hydrazide, isonicotinic acid hydrazide, methyl nicotinate, methyl isonicotinate, sodium nicotinate, pyridoxine hydrochloride, 4-propanol pyridine and 2-propanol pyridine.  The molecular ratio of tetracycline: alkaline earth ions: pyridine compound is at least 1:1:4 or 1: 1/2 :40 and is preferably 1:2,5:8. For parenteral administration there may be present a soluble, non-toxic alpha hydroxy acid or a salt thereof.  Other additions are (a) anaesthetic e.g. procaine (b) analgesic e.g. antipyrine (c) stabiliser e.g. sodium sulphite.  Specification 793,558 is referred to.
BACKGROUNDS: Cognitive frailty, a clinical syndrome with physical frailty and cognitive impairment, leads to mortality and other adverse health outcomes in older adults. This study aimed to investigate the prevalence of cognitive frailty, and its influencing factors, and follow its impact on short-term mortality in elderly chronic obstructive pulmonary disease patients, to provide a theoretical scientific reference basis for clinical intervention and management of cognitive frailty.
METHODS: A sample of 243 elderly chronic obstructive pulmonary disease patients in the respiratory department of a tertiary care hospital was conveniently sampled from November 2021 to February 2023, and the prevalence of cognitive frailty was investigated using the General Information Survey Scale, the Fried Phenotype Scale, the Mini-Mental State Examination, the Anxiety Self-Rating Scale, the Brief Geriatric Depression Scale, and the Mortality Record. The mortality was recorded by telephone follow-up after 6 months. A database was created and statistical analysis such as one-way analysis of variance, logistic regression analysis, Kaplan-Meier, and Cox survival analysis were used to analyze the data.
RESULTS: A total of 47 patients (19.3%) had cognitive frailty; there were statistical differences in the prevalence of cognitive frailty by medical payment type, physical exercise, and sleeping time (P < 0.05). During a 6-month follow-up, 38 patients (15.6%) died. Cox survival analysis showed that the risk of death in elderly chronic obstructive pulmonary disease patients in the cognitive frailty group was 3.212 times higher than that in the normal cognitive function and non-frailty group (95% CI 1.646-6.270, P = 0.001), and 5.266 times higher than that in the normal cognitive function and frailty group (95% CI 3.159-8.778, P < 0.001).
CONCLUSIONS: The prevalence of cognitive frailty in elderly chronic obstructive pulmonary disease patients is high, and clinical staff should pay attention to patients' medical burden and financial ability, and reduce the incidence of cognitive frailty by instructing patients to perform physical exercise and arrange sleep time. Cognitive frailty is an important risk factor for mortality within 6 months in elderly chronic obstructive pulmonary disease patients, and early intervention should be emphasised to reduce or delay cognitive frailty and mortality.
In a clinical study in patients with Type 2 diabetes, nateglinide was administered in increasing doses up to 720 mg a day for 7 days and there were no clinically significant adverse events reported. There have been no instances of overdose with nateglinide in clinical trials. However, an overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms. Hypoglycemic symptoms without loss of consciousness or neurological findings should be treated with oral glucose and adjustments in dosage and/or meal patterns. Severe hypoglycemic reactions with coma, seizure, or other neurological symptoms should be treated with intravenous glucose. As nateglinide is highly protein bound, dialysis is not an efficient means of removing it from the blood.
BACKGROUND & AIMS: The management of acute kidney injury (AKI) in cirrhosis is challenging. The EASL guidelines proposed an algorithm for the management of AKI, but this has never been validated. We aimed to prospectively evaluate this algorithm in clinical practice.
METHODS: We performed a prospective cohort study in consecutive hospitalized patients with cirrhosis and AKI. The EASL management algorithm includes identification/treatment of precipitating factors, 2-day albumin infusion in patients with AKI ≥stage 1B, and treatment with terlipressin in patients with hepatorenal syndrome (HRS-AKI). The primary outcome was treatment response, which included both full and partial response. Secondary outcomes were survival and adverse events associated with terlipressin therapy.
RESULTS: A total of 202 AKI episodes in 139 patients were included. Overall treatment response was 80%, while renal replacement therapy was required in only 8%. Response to albumin infusion was achieved in one-third of episodes. Of patients not responding to albumin, most (74%) did not meet the diagnostic criteria of HRS-AKI, with acute tubular necrosis (ATN) being the most common phenotype. The response rate in patients not meeting the criteria for HRS-AKI was 70%. Only 30 patients met the diagnostic criteria for HRS-AKI, and their response rate to terlipressin was 61%. Median time from AKI diagnosis to terlipressin initiation was only 2.5 days. While uNGAL (urinary neutrophil gelatinase-associated lipocalin) could differentiate ATN from other phenotypes (AUROC 0.78), it did not predict response to therapy in HRS-AKI. Ninety-day transplant-free survival was negatively associated with MELD-Na, ATN and HRS-AKI as well as uNGAL. Three patients treated with terlipressin developed pulmonary edema.
CONCLUSIONS: The application of the EASL AKI algorithm is associated with very good response rates and does not significantly delay initiation of terlipressin therapy.
IMPACT AND IMPLICATIONS: The occurrence of acute kidney injury (AKI) in patients with cirrhosis is associated with poor short-term mortality. Improving its rapid identification and prompt management was the focus of the recently proposed EASL AKI algorithm. This is the first prospective study demonstrating that high AKI response rates are achieved with the use of this algorithm, which includes identification of AKI, treatment of precipitating factors, a 2-day albumin challenge in patients with AKI ≥1B, and supportive therapy in patients with persistent AKI not meeting HRS-AKI criteria or terlipressin with albumin in those with HRS-AKI. These findings support the use of this algorithm in clinical practice.
In this study, 300 patients will be enrolled. Eligible patients will be those with histologically confirmed epithelial ovarian cancer, carcinoma of fallopian tube or primary peritoneal carcinoma. Patients must have received one line of platinum-based chemotherapy, and be in clinically complete or partial response following the platinum-based chemotherapy prior to enrollment in the study. Patients will be treated with Niraparib according to the physician's judgement till disease progression, discontinuation for other reasons or death. The primary endpoint is treatment pattern of Niraparib as first-line maintenance treatment for ovarian cancer patients. The second endpoints include AE, PFS and quality of life.
PURPOSE:To provide the titled composition containing an enediolcompound, a copper compound and a specific carboxylic acid as essential components. CONSTITUTION:The objective antimicrobial agent composition having specifically stabilized and prolonged antimicrobial activity can be prepared by using (A) 0.01-10 (wt)% enediol compound (e.g. ascorbic acid, dihydroxymaleic acid and their derivatives) (based on the whole composition), (B) 0.0001-0.1% copper compound (e.g. cupric chloride, cupric sulfate, etc.) and (C) 0.01-10% 6-10C dicarboxylic acid (e.g. adipic acid, pimelic acid, sebacic acid, stc. as essential components. When the amount of the dicarboxylic acid is too low, sufficient effect cannot be expected, and when it is too high, there occurs various problems such as the side effect of dicarboxylic acid and the formation of precipitate, etc. The composition is useful as cleaning and sterilizing agent for contact lens, gargle, cleaning and sterilizing agent for denture, cleaning agent for toilet and bathtub, anhidrotic spray, etc.
Anorexia nervosa (AN) is a serious psychiatric disease, but the neural mechanisms underlying its development are unclear. A subpopulation of amygdala neurons, marked by expression of protein kinase C-delta (PKC-δ), has previously been shown to regulate diverse anorexigenic signals. Here, we demonstrate that these neurons regulate development of activity-based anorexia (ABA), a common animal model for AN. PKC-δ neurons are located in two nuclei of the central extended amygdala (EAc): the central nucleus (CeA) and oval region of the bed nucleus of the stria terminalis (ovBNST). Simultaneous ablation of CeAPKC-δ and ovBNSTPKC-δ neurons prevents ABA, but ablating PKC-δ neurons in the CeA or ovBNST alone is not sufficient. Correspondingly, PKC-δ neurons in both nuclei show increased activity with ABA development. Our study shows how neurons in the amygdala regulate ABA by impacting both feeding and wheel activity behaviors and support a complex heterogeneous etiology of AN.
Statins are thought to have positive effects on migraine but existing data are inconclusive. We aimed to evaluate the causal effect of such drugs on migraines using Mendelian randomization. We used four types of genetic instruments as proxies for HMG-CoA reductase inhibition. We included the expression quantitative trait loci of the HMG-CoA reductase gene and genetic variation within or near the HMG-CoA reductase gene region. Variants were associated with low-density lipoprotein cholesterol, apolipoprotein B, and total cholesterol. Genome-wide association study summary data for the three lipids were obtained from the UK Biobank. Comparable data for migraine were obtained from the International Headache Genetic Consortium and the FinnGen Consortium. Inverse variance weighting method was used for the primary analysis. Additional analyses included pleiotropic robust methods, colocalization, and meta-analysis. Genetically determined high expression of HMG-CoA reductase was associated with an increased risk of migraines (OR = 1.55, 95% CI 1.30-1.84, P = 6.87 × 10-7). Similarly, three genetically determined HMG-CoA reductase-mediated lipids were associated with an increased risk of migraine. These conclusions were consistent across meta-analyses. We found no evidence of bias caused by pleiotropy or genetic confounding factors. These findings support the hypothesis that statins can be used to treat migraine.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use capable of not only synergistically improving preventing and reducing effects on the skin roughening but also causing slight irritation to the skin by combining a placental extract collected from an extracted solution derived from the placenta of a vertebrate with a specific compound. SOLUTION: This skin preparation for external use is obtained by combining a placental extract with a low-molecular weight betaine. The placental extract is preferably derived from the bovine placenta. The low-molecular weight betaine preferably includes quaternary ammonium salts of the formula (R<1> to R<3> are each a 1-6C alkyl, with the proviso that the total number of carbon atoms in the R<1> to R<3> is 8 or less). The placental extract is blended in an amount of preferably 0.01-5wt.%, more preferably 0.1-0.5wt.% based on the total weight of the skin preparation for external use. The low-molecular weight betaine is blended in an amount of preferably 0.01-30wt.%, more preferably 0.1-10wt.% based on the total weight of the skin preparation for external use.  The skin preparation for external use includes all that are applied to the exodermis such as cosmetics, medicines and quasi-drugs.
Heart rate variability (HRV) is a noninvasive approach to studying the autonomic modulation of heart rate in experimental settings, such as active standing sympathetic stimulation. It is known that patients with end-stage renal disease during active standing have few changes in HRV dynamics, which are improved after hemodialysis. However, it is unknown whether the response to active standing is recovered after definitive treatment with kidney transplantation. This work aims to assess the change in HRV dynamics in the supine position and active standing through time and frequency-based metrics, as well as recurrence plot quantitative analysis (RQA). We studied HRV dynamics by obtaining 5-minute electrocardiographic recordings from kidney transplant recipients who underwent an active standing test. The mean duration of heartbeats and their standard deviation diminished in active standing, compared with the supine position. Also, the low-frequency component of HRV and the presence of diagonal and vertical structures in RQA were predominant. A larger estimated glomerular filtration rate was significantly correlated with broader HRV in the supine position and during active standing. The narrower HRV during active standing may indicate a sympathetic response to external stimuli, which is expected in a functional cardiovascular system, and may be influenced by renal function.
Group (2): Twenty patients will receive both 2000 pulses of (Focused shockwave therapy with (4 Hz; 0.2 mJ/mm2) and 2000 pulses of Radial shockwave therapy with (8 Hz, 2.5 bars) )= combined shockwave therapy in addition to conventional therapy including eccentric exercises, stretching, hot packs and deep transverse friction(Johnson et al., 2007). Each patient will have 3 treatment sessions held at weekly basis(Król et al., 2015).
Cervical cancer (CC) remains a major cause of cancer-related mortality among women globally. Long noncoding RNAs (lncRNAs) play crucial regulatory roles in various cancers, including CC. This study investigates the function of a novel lncRNA, USP30 antisense RNA 1 (USP30-AS1), in CC tumorigenesis. We analyzed USP30-AS1 expression using RT-qPCR and conducted in vitro loss-of-function assays, as well as in vivo assays, to evaluate the effects of USP30-AS1 silencing on CC cell growth and migration. Additional mechanistic experiments, including RNA pull-down, RNA immunoprecipitation (RIP), and co-immunoprecipitation (Co-IP) assays, were performed to elucidate the regulatory mechanisms influenced by USP30-AS1. We discovered that USP30-AS1 is overexpressed in CC tissues and cells. Silencing USP30-AS1 significantly reduced cell proliferation, migration, invasion, and tumor growth. Moreover, USP30-AS1 was found to modulate the expression of ubiquitin-specific peptidase 30 (USP30) by sponging microRNA-2467-3p (miR-2467-3p) and recruiting the FUS RNA binding protein (FUS), thereby stabilizing β-catenin and activating the Wnt/β-catenin signaling pathway. These findings suggest that USP30-AS1 enhances CC cell growth and migration through the miR-2467-3p/FUS/USP30 axis, highlighting its potential as a biomarker for CC.
The first experimental group will have access to an online self-help program for depression. The program Deprexis® is a self-help, web-based intervention that proposed various modules to face depression. They will have access to the program for 8 weeks. They are asked to complete the modules as many times as they wish and to use to program at least 30 minutes, 1 or 2 times a week. They will be assessed at baseline (T0), mid-intervention (4-weeks, T1), post-intervention (8-weeks, T2) and for the follow-up (3 months post intervention, T3). They will be asked to complete online questionnaires.
An energy-saving and water-saving water supply equipment for hospital. The utility model belongs to the technical field of water processing. The utility model provides an energy saving and water saving equipment for outdoors, which has the advantages of small size, light weight, long service life, wide adaptability, as well as good maneuverability, and is a mini-type water processing equipment which is convenient for transportation and transfer. In the condition of field warfare, various natural water such as river water, well water and pool water can be used as raw water. By the technical processes of raw water pretreatment, filtering absorbing, I level ultrafiltration, ion-exchange and II level ultrafiltration, water for injection which conforms to the standard in the China pharmacopoeia of 1985 edition can be obtained. The equipment is suitable for the practical use of military filed hospitals and other medical units which need to move frequently.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

VUITY dosed once daily was evaluated in 375 participants with presbyopia in two randomized, double-masked, vehicle-controlled studies (GEMINI 1 and GEMINI 2) of 30 days duration. The most common adverse reactions reported in >5% of participants were headache and conjunctival hyperemia. Ocular adverse reactions reported in 1-5% of participants were blurred vision, eye pain, visual impairment, eye irritation, and increased lacrimation.

VUITY was also evaluated in 114 participants with presbyopia in a randomized, double-masked, vehicle-controlled 14-day study (VIRGO) in which participants received two doses of VUITY in each eye, 6 hours apart daily. The most common adverse reactions reported in >5 % of participants were headache and eye irritation. Ocular adverse reactions reported in 1-5% of participants were visual impairment, eye pain, blurred vision, and vitreous floaters.
The invention discloses an agent for angina pectoris of coronary heart disease and preparation method thereof. The angina pectoris of coronary heart disease is common ailment and frequently-occurring disease in the middle-aged and the elderly population. The chinese medicine is comparatively effective for angina pectoris of coronary heart disease. It is an innovative duty to explore the medicine and medicine composition for angina pectoris of coronary heart disease. The agent is prepared by compatibility of drugs such as panax, notoginseng, astragalus, safflower, red sange root, corydalis tuber. After clinical verification, the results show that the total effectiveness ratio of therapy of angina pectoris is 92.86%, wherein the remarkable effective rate is 62.05%; and the effectiveness ratio of improving the clinical symptom is 92.74%, wherein the remarkable effective rate is 65.02%; and the total effectiveness ratio of improving of cardiogram is 53.80%, wherein the remarkable effective rate is 26.73%; at last through colligating the above curative effect and statistical treatment, the total effectiveness ratio of therapy of chest stuffiness and pains is 91.09%, wherein the remarkable effective rate is 47.85%.
The invention relates to a method for recognizing an event. In this case, at the beginning in a method step a, at least one first measurement value pattern (22) which characterizes the event is detected and stored. Subsequently, in a method step b, a holder exponent is determined multifractally depending on the first measurement value pattern (22). Afterward, in a method step c, a mother wavelet is determined depending on the holder exponent. In a subsequent method step d, a plurality of measurement values (32) of a sensor unit (30) are detected within a time period. Then, in a method step e, transformed measurement values are generated by a wavelet transformation of the detected measurement values (32) depending on the mother wavelet determined. Afterward, in a method step f, the transformed measurement values are compared with a stored limit value. If at least one of the transformed measurement values exceeds the limit value, the fact that the event has occurred is identified in a method step g. Finally, a signal (42) which signals that the event has occurred is generated in a method step h. The invention additionally relates to a device (10) comprising a processing unit (20) and a sensor unit (30), wherein the processing unit (20) is configured to carry out a method according to the invention.
Miochol™-E (acetylcholine chloride intraocular solution) is a parasympathomimetic preparation for intraocular use. It is packaged in a blister pack containing one vial and one diluent ampule. The vial contains 20 mg acetylcholine chloride and 56 mg mannitol. The accompanying ampule contains 2 mL of a modified diluent of calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, sodium acetate trihydrate, and sterile water for injection.

The reconstituted liquid will be a sterile isotonic solution (275–330 milliosmoles/kg) containing 20 mg acetylcholine chloride (1:100 solution) and 2.8% mannitol. The pH range is 5.0–8.2. Mannitol is used in the process of lyophilizing acetylcholine chloride, and is not considered an active ingredient.

The chemical name for acetylcholine chloride, C7H16ClNO2, is Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, chloride and is represented by the following chemical structure:
The second type, called "B" Cohorts, corresponds to indications for which a role of the immune system is suspected. Only the so-called "informative" patients (responders or surprising evolution) will have one lymphapheresis during treatment. The lymphapheresis will be performed between 8 weeks and 18 months after the start of treatment and depending on the clinical course determined by the clinicians in consultation with at least one immunologist (Olivier Lantz, Emanuela Romano, Cécile Alanio, Marion Alcantara).